TY - JOUR
T1 - Temperature-sensitive copolymer-coated fluorescent mesoporous silica nanoparticles as a reactive oxygen species activated drug delivery system
AU - Yu, Feng
AU - Wu, Huijing
AU - Tang, Yao
AU - Xu, Yufang
AU - Qian, Xuhong
AU - Zhu, Weiping
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/1/30
Y1 - 2018/1/30
N2 - In this study, a temperature and ROS-responsive drug delivery system ROSP@MSN based on mesoporous silica nanoparticles has been designed and synthesized by taking advantage of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acrylate modified polymers (ROSP) as “nano-valve”, which can respond selectively to cancer exclusive microenvironment and implement targeted drug release. Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX. Upon the stimulus of ROS, ROSP@MSN@DOX shows good release performance at physiological conditions. The cytotoxicity study demonstrates that the cell viability is about 80% after Hela cells are treated with ROSP@MSN at a concentration of 100 μg/mL for 24 h, exhibiting the good biocompatibility of ROSP@MSN. Furthermore, after treated with ROSP@MSN@DOX at a concentration of 100 μg/mL for 24 h, the viability of Hela cells is reduced to 40.5%; Control experiments demonstrate that, when Hela cells are pretreated with active oxygen scavenger, cell viability is about 65.3% due to the significant decrease of intracellular reactive oxygen species. Therefore, the therapeutic nanocarrier with effective encapsulation and release capacity in particular situation is a great candidate for the new drug delivery platform for targeted cancer therapy.
AB - In this study, a temperature and ROS-responsive drug delivery system ROSP@MSN based on mesoporous silica nanoparticles has been designed and synthesized by taking advantage of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acrylate modified polymers (ROSP) as “nano-valve”, which can respond selectively to cancer exclusive microenvironment and implement targeted drug release. Due to the superior temperature-sensitive properties of ROSP, ROSP@MSN could achieve cargo loading in cold water, and subsequently close the pore by raising temperature to obtain ROSP@MSN@DOX. Upon the stimulus of ROS, ROSP@MSN@DOX shows good release performance at physiological conditions. The cytotoxicity study demonstrates that the cell viability is about 80% after Hela cells are treated with ROSP@MSN at a concentration of 100 μg/mL for 24 h, exhibiting the good biocompatibility of ROSP@MSN. Furthermore, after treated with ROSP@MSN@DOX at a concentration of 100 μg/mL for 24 h, the viability of Hela cells is reduced to 40.5%; Control experiments demonstrate that, when Hela cells are pretreated with active oxygen scavenger, cell viability is about 65.3% due to the significant decrease of intracellular reactive oxygen species. Therefore, the therapeutic nanocarrier with effective encapsulation and release capacity in particular situation is a great candidate for the new drug delivery platform for targeted cancer therapy.
KW - Controlled delivery system
KW - Mesoporous silica nanoparticles
KW - Reactive oxygen species
KW - Stimuli-responsive system
UR - https://www.scopus.com/pages/publications/85034840215
U2 - 10.1016/j.ijpharm.2017.11.025
DO - 10.1016/j.ijpharm.2017.11.025
M3 - 文章
C2 - 29146540
AN - SCOPUS:85034840215
SN - 0378-5173
VL - 536
SP - 11
EP - 20
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1
ER -